Paresh Vyas

44.4k citations

235 papers · 9.4k indexed · 2 hit papers · h-index 52

Impact in

Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 178
- Acute Myeloid Leukemia Research 148
- Chronic Myeloid Leukemia Treatments 33
- Multiple Myeloma Research and Treatments 22
- Hematopoietic Stem Cell Transplantation 20
Genetics 79
- Myeloproliferative Neoplasms: Diagnosis and Treatment 38
- Hemoglobinopathies and Related Disorders 24

Co-authors: Stuart H. Orkin Charles Craddock Irene Roberts Catherine Porcher Ramesh A. Shivdasani Ravindra Majeti Douglas R. Higgs Carl W. Jackson
Journals: Blood (75 papers)Journal of Clinical Oncology (16 papers)British Journal of Haematology (10 papers)Haematologica (7 papers)HemaSphere (6 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Paresh Vyas

226 papers receiving 9.2k citations

Hit Papers

align trajectories log scale

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia 2012 · 522 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Science Translational Medicine
2001 The Lancet Oncology

Peers

Countries citing papers authored by Paresh Vyas

Since Specialization

Citations

This map shows the geographic impact of Paresh Vyas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paresh Vyas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paresh Vyas more than expected).

Fields of papers citing papers by Paresh Vyas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paresh Vyas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paresh Vyas. The network helps show where Paresh Vyas may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paresh Vyas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paresh Vyas Line = papers co-authored together Paresh Vyas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo Blood ·Lisa D. Johnson, Stephanie Y. Kang, Н.С. Холод, Marlen Metzner, Santos Ar, François G. Kavelaars, Yoga Priawan, Anne E. Lawson, Kenneth J. Caldwell, Peter J.M. Valk, Paresh Vyas	2024	1
2	A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia. Journal of Clinical Oncology ·Naval Daver, Pau Montesinos, Jessica K. Altman, Anjali S. Advani, Eunice S. Wang, Sylvain Garciaz, Giovanni Martinelli, Gail J. Roboz, Roland B. Walter, Kebede H. Begna, Monia Lunghi, Uwe Platzbecker, Paresh Vyas, Patrick W. Burke, Antonio Curti, Daniel J. DeAngelo, Lauris Gastaud, Christoph Schliemann, Benjamin Oshrine, David A. Sallman	2024	1
3	Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved Science Immunology ·Lakshmi B. Subadhra, Grigore Gafencu, Bilyana Stoilova, Mario Buono, Ying Zhang, Sven Turkalj, Yiran Meng, Niels Asger Jakobsen, Marlen Metzner, Sally‐Ann Clark, D. E. Ruhen, Supat Thongjuea, Paresh Vyas, Claus Nerlov	2024	10
4	Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia RSC Medicinal Chemistry ·N Mutlu, W S Pranowo, Ester Garne, Sébastien R. G. Galan, Tongzhou Qu, Sergey V. Galaktionov, Carole J. R. Bataille, Thomas Jackson, たけし峰, Stephen G. Davies, Paresh Vyas, Thomas A. Milne, Graham M. Wynne, Angela J. Russell	2024	1
5	Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines European Journal of Medicinal Chemistry ·W S Pranowo, Sébastien R. G. Galan, N Mutlu, Thomas Jackson, Tongzhou Qu, Eva Allione, Young-Beom Jeong, Tom S. Carter, Justin T. Lana, Glyn Coxhill, たけし峰, Carole J. R. Bataille, Stephen G. Davies, Paresh Vyas, Thomas A. Milne, Alan Naylor, Graham M. Wynne, Angela J. Russell	2023	5
6	TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions Cancer Discovery ·Naval Daver, Abhishek Maiti, Tapan M. Kadia, Paresh Vyas, Ravindra Majeti, Andrew H. Wei, Guillermo Garcia‐Manero, Charles Craddock, David A. Sallman, Hagop M. Kantarjian	2022	83
7	Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy British Journal of Haematology ·Justin Loke, Marlen Metzner, Rebecca H. Boucher, Aimee Jackson, Norah Badr Alruwaili, Jiří Pavlů, Eleni Tholouli, Mark W. Drummond, Andy Peniket, Rebecca Bishop, Sonia Fox, Paresh Vyas, Charles Craddock	2021	3
8	Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features Blood ·Damien Roos‐Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, Seres Tamás, Marlen Metzner, Junyan Lu, Magali Le Garff‐Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen‐Khac, Olivier Bernard, Christopher C. Oakes	2020	6
9	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia Blood Advances ·Kosato Kinoshita, Lynn Quek, Itamar S Santos, Elene Sikharulidze, Juan Luiz Coelho‐Silva, Diego A. Pereira‐Martins, Grant Vallance, Benjamin Brown, 亮吏藤井, Paulo César Martins Bitarães, Elvira Deolinda Rodrigues Pereira Velloso, Antonio R. Lucena‐Araujo, Fabı́ola Traina, Andy Peniket, Paresh Vyas, Eduardo Magalhães Rego, Israel Bendit, Vanderson Rocha	2020	10
10	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings? Leukemia & lymphoma ·Kosato Kinoshita, Juan Luiz Coelho‐Silva, Paulo César Martins Bitarães, Grant Vallance, Diego A. Pereira‐Martins, Krystyna Maruszko, Lorena Lôbo de Figueiredo-Pontes, Elvira Deolinda Rodrigues Pereira Velloso, Belinda Pinto Simões, Andy Peniket, Robert Danby, Eduardo Magalhães Rego, Paresh Vyas, Fabı́ola Traina, Israel Bendit, Lynn Quek, Vanderson Rocha	2020	6
11	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study Blood ·Geoffrey L. Uy, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Sreejith V Ravi, Paresh Vyas, Yngvar Fløisand, María‐Belén Vídriales, Bjørn Tore Gjertsen, Jordi Esteve, Tonia J. Buchholz, Suzana S. Couto, Jinhong Fan, Bishoy Hanna, Li Li, Daniel W. Pierce, Kristen Hege, Michael Pourdehnad, Amer M. Zeidan	2019	23
12	SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells Nature Communications ·Hédia Chagraoui, Maiken Søndergaard Kristiansen, Juan Pablo Ruíz, DiBenedetto DJ, Johanna Richter, S Gyaneswar Singh, Nicki Gray, Dominic Waithe, Kevin Clark, Philip Hublitz, Emmanouela Repapi, Georg Otto, Paul Sopp, Stephen Taylor, Supat Thongjuea, Paresh Vyas, Catherine Porcher	2018	26
13	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Blood ·Michael Amatangelo, Lynn Quek, Alan H. Shih, Eytan M. Stein, Mikhail Roshal, Muriel D. David, Benoît Marteyn, Noushin Farnoud, Stéphane de Botton, Olivier Bernard, Bin Wu, Katharine Yen, Martin S. Tallman, Elli Papaemmanuil, Virginie Penard‐Lacronique, Anjan Thakurta, Paresh Vyas, Ross L. Levine	2017	249
14	Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells Nature Immunology ·Dimitris Karamitros, Bilyana Stoilova, Celia Angela Alonso Rodríguez, Fiona Hamey, Andreas Reinisch, W. Pabon, Lynn Quek, Georg Otto, Emmanouela Repapi, Jessica Doondeea, Batchimeg Usukhbayar, Julien Calvo, Stephen Taylor, Nicolas Goardon, Emmanuelle Six, Françoise Pflumio, Catherine Porcher, Ravindra Majeti, Berthold Göttgens, Paresh Vyas	2017	144
15	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes Journal of Clinical Investigation ·Bon Ham Yip, Violetta Steeples, Emmanouela Repapi, Richard N. Armstrong, Miriam Llorian, Swagata Roy, Jacqueline Shaw, Hamid Dolatshad, Stephen Taylor, Amit Verma, Matthias Bartenstein, Paresh Vyas, Nicholas C.P. Cross, Luca Malcovati, Mario Cazzola, Eva Hellström‐Lindberg, Seishi Ogawa, Christopher W. J. Smith, Andrea Pellagatti, Jacqueline Boultwood	2017	70
16	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia Blood Advances ·Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, Michael R. Hamblin, Mayra Viviana Medrano Medina, Richard E. Clark, Mhairi Copland, Paresh Vyas	2016	9
17	COMBINED ANALYSES OF ROS, CELL CYCLE AND IMMUNOPHENOTYPE SHOWS THAT NORMAL HEMATOPOIETIC PROGENITOR SUBSETS HAVE A DIFFERENTIAL ROS PROFILE THAT IS LOST IN ACUTE MYELOID LEUKEMIA Haematologica ·Arwa A Alrrzqi, Paresh Vyas, Charlotte Bradbury, Peter Richardson, Manoj Raghavan, Charles Craddock, David Grimwade, Sylvie Freeman	2013	1
18	MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY Cytometry Part A ·Cristina Picone, Fran Soljacic, Laura Vanelli, Luca Malcovati, Cristiana Pascutto, Kíyoyuki Ogata, Hideto Tamura, Salvatore Rappoccio, Magdalena Czader, Sylvie Freeman, Paresh Vyas, Anna Porwit, Mochamad Badar Ranu Widakso, Theresia M. Westers, Canan Alhan, Claudia Cali, Arjan A. van de Loosdrecht, Mario Cazzola, Matteo Giovanni Della Porta	2011	1
19	Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations Blood ·J. M. Ven l inen, Anindita Roy, Anastasios Karadimitris, Josu de la Fuente, Nicholas M. Fisk, Phillip R. Bennett, Alice Norton, Paresh Vyas, Irene Roberts	2008	99
20	Cerebral venous sinus thrombosis in polycythaemia British Journal of Hospital Medicine ·Dorothy Thomson, Paresh Vyas, M S Hammersley	2008	1

About Paresh Vyas

Paresh Vyas is a scholar working on Hematology, Genetics, Immunology, Molecular Biology and Cancer Research, having authored 235 papers that have together received 9.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (148 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (38 papers), Chronic Myeloid Leukemia Treatments (33 papers), Epigenetics and DNA Methylation (25 papers), Hemoglobinopathies and Related Disorders (24 papers), Multiple Myeloma Research and Treatments (22 papers), Hematopoietic Stem Cell Transplantation (20 papers) and Acute Lymphoblastic Leukemia research (20 papers). The work is most often cited by research in Hematology (5.1k citations), Genetics (1.8k citations), Immunology (1.8k citations), Molecular Biology (4.4k citations) and Cancer Research (899 citations). Paresh Vyas has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Stuart H. Orkin, Charles Craddock, Irene Roberts, Catherine Porcher, Ramesh A. Shivdasani, Ravindra Majeti, Douglas R. Higgs, Carl W. Jackson, Kenneth A. Ault and Irving L. Weissman. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Haematologica and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact